It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-18 00:18:41 Source:opinionsViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Open letter before European Parliament election: Prioritize democracy as authoritarianism grows
Next:In boost to Olympic ambitions, Istanbul moves closer to hosting 2027 European Games.
You may also like
- A Palestinian converted to Judaism. An Israeli soldier saw him as a threat and opened fire
- Tencent's AI technology to find pulsars 'FASTER'
- Northerners head south for warmth
- China's homemade subsea oil drilling equipment put into use in Zhanjiang
- Biden marks Brown v. Board of Education anniversary amid signs of erosion in Black voter support
- EU set to fine Apple $540 mln for unfair play
- China launches space
- China registers 415 million motor vehicles, 500 million drivers
- Michael Cohen is torn to shreds by Trump's attorneys in blistering cross